{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroenteropancreatic+Neuroendocrine+Carcinoma",
    "query": {
      "condition": "Gastroenteropancreatic Neuroendocrine Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroenteropancreatic+Neuroendocrine+Carcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T01:31:03.454Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02936323",
      "title": "PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "Carcinoma, Small Cell Lung",
        "Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "PEN-221",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarveda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2016-12-08",
      "completion_date": "2021-02-25",
      "has_results": true,
      "last_update_posted_date": "2021-12-14",
      "last_synced_at": "2026-06-26T01:31:03.454Z",
      "location_count": 10,
      "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02936323"
    },
    {
      "nct_id": "NCT02709889",
      "title": "Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma",
        "Medullary Thyroid Cancer",
        "Glioblastoma",
        "Large-Cell Neuroendocrine Carcinoma",
        "Neuroendocrine Prostate Cancer",
        "High Grade Gastroenteropancreatic Neuroendocrine Carcinoma",
        "Other Neuroendocrine Carcinoma",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Rovalpituzumab tesirine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 200,
      "start_date": "2016-09-23",
      "completion_date": "2019-08-27",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-06-26T01:31:03.454Z",
      "location_count": 30,
      "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02709889"
    },
    {
      "nct_id": "NCT07488923",
      "title": "A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer (SCLC )",
        "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)",
        "Gastroenteropancreatic NEC (GEP NEC)",
        "Neuroendocrine Prostate Cancer (NEPC)"
      ],
      "interventions": [
        {
          "name": "ML261",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Moonlight Bio, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2026-06",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-06-26T01:31:03.454Z",
      "location_count": 5,
      "location_summary": "Hackensack, New Jersey • New York, New York • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07488923"
    },
    {
      "nct_id": "NCT05477576",
      "title": "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "GEP-NET",
        "Gastroenteropancreatic Neuroendocrine Tumor",
        "Gastroenteropancreatic Neuroendocrine Tumor Disease",
        "Neuroendocrine Tumors",
        "Carcinoid",
        "Carcinoid Tumor",
        "Pancreatic NET"
      ],
      "interventions": [
        {
          "name": "RYZ101",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib",
          "type": "DRUG"
        },
        {
          "name": "Octreotide",
          "type": "DRUG"
        },
        {
          "name": "Lanreotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RayzeBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 338,
      "start_date": "2022-03-24",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-06-26T01:31:03.454Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 27 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05477576"
    },
    {
      "nct_id": "NCT05064150",
      "title": "Neuroendocrine Tumors - Patient Reported Outcomes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuroendocrine Tumors",
        "Gastroenteropancreatic Neuroendocrine Tumor",
        "Lung Neuroendocrine Neoplasm",
        "Neuroendocrine Carcinoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2539,
      "start_date": "2022-05-10",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-06-26T01:31:03.454Z",
      "location_count": 14,
      "location_summary": "Gainesville, Florida • Iowa City, Iowa • Kansas City, Kansas + 11 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05064150"
    },
    {
      "nct_id": "NCT02595424",
      "title": "Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Neuroendocrine Carcinoma",
        "Intestinal Neuroendocrine Carcinoma",
        "Pancreatic Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2015-11-06",
      "completion_date": "2029-01-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-06-26T01:31:03.454Z",
      "location_count": 673,
      "location_summary": "Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more",
      "locations": [
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Antioch",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595424"
    },
    {
      "nct_id": "NCT00690430",
      "title": "Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Symptomatic Refractory Resistant Carcinoid Disease"
      ],
      "interventions": [
        {
          "name": "Pasireotide",
          "type": "DRUG"
        },
        {
          "name": "Octreotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 186,
      "start_date": "2008-04",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2013-07-30",
      "last_synced_at": "2026-06-26T01:31:03.454Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Loma Linda, California + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00690430"
    },
    {
      "nct_id": "NCT05652686",
      "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer (SCLC)",
        "Large Cell Neuroendocrine Cancer (LCNEC)",
        "Neuroendocrine Prostate Cancer (NEPC)",
        "Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)",
        "Neuroendocrine Carcinomas (NEC)",
        "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)"
      ],
      "interventions": [
        {
          "name": "Peluntamig (PT217)",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel.",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phanes Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 203,
      "start_date": "2023-09-05",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-06-26T01:31:03.454Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Denver, Colorado • Baltimore, Maryland + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05652686"
    },
    {
      "nct_id": "NCT07080242",
      "title": "Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer Metastatic or Locally Advanced",
        "Neuroendocrine Cancer",
        "Metastatic Neuroendocrine Prostate Cancer",
        "Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma",
        "Metastatic Advanced Merkel Cell Carcinoma",
        "Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung",
        "Locally Advanced Extrapulmonary Neuroendocrine Carcinoma",
        "Locally Advanced Neuroendocrine Prostate Cancer",
        "Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine",
        "Locally Advanced Merkel Cell Carcinoma",
        "Metastatic Large Cell Neuroendocrine Carcinoma of the Lung"
      ],
      "interventions": [
        {
          "name": "BL-M14D1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SystImmune Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2025-04-28",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-26T01:31:03.454Z",
      "location_count": 20,
      "location_summary": "Huntsville, Alabama • Los Angeles, California • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07080242"
    },
    {
      "nct_id": "NCT07278479",
      "title": "Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Large Cell Neuroendocrine Carcinoma",
        "Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)",
        "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)",
        "Small Cell Lung Cancer (SCLC)",
        "Gastroenteropancreatic NEC (GEP NEC)",
        "NEC of the Bladder",
        "Other DLL3 Expressing epNEC"
      ],
      "interventions": [
        {
          "name": "[212Pb]Pb-MP0712",
          "type": "DRUG"
        },
        {
          "name": "[203Pb]Pb-MP0712",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Molecular Partners AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2026-05-18",
      "completion_date": "2032-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-26T01:31:03.454Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Glen Burnie, Maryland • Omaha, Nebraska + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07278479"
    }
  ]
}